Friday, June 6, 2014

News: Bayer HealthCare To Evaluate Riociguat In New Indication - Quick Facts

RTTNews - Bayer HealthCare announced the start of a randomized, double-blind, placebo-controlled Phase IIb study. The RISE-IIP study or Riociguat in patients with Symptomatic Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonias is designed to investigate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension or PH associated with idiopathic interstitial pneumonia or IIP.

Read article | Learn more about other PH clinical trials

No comments: